Roughly 2.3 million women are diagnosed with breast cancer worldwide each year, making it the most commonly diagnosed cancer on the planet. In the United States alone, an estimated 310,000 new cases of invasive breast cancer are expected annually, with an additional 48,000 cases of non-invasive breast cancer (DCIS) diagnosed each year. Those numbers have been slowly climbing in certain age groups, even as survival rates continue to improve.
Global and U.S. Numbers at a Glance
The World Health Organization estimated 2.3 million new breast cancer diagnoses and 670,000 breast cancer deaths globally in 2022. The burden is not evenly distributed. High-income countries tend to have higher incidence rates, partly because of wider screening access that catches more cases, but lower-income countries often face higher mortality because diagnosis comes later and treatment is harder to access.
In the U.S., invasive breast cancer accounts for roughly 310,000 new diagnoses per year among women. On top of that, more than 48,000 women are diagnosed annually with ductal carcinoma in situ, a non-invasive form where abnormal cells are found in the milk ducts but haven’t spread into surrounding tissue. DCIS is almost always caught on a mammogram and has an excellent prognosis, but it’s tracked separately from invasive cases in most statistics.
About 1 out of every 100 breast cancers diagnosed in the U.S. is found in a man. That translates to roughly 2,800 cases per year in men, a small but real number that often gets overlooked.
Who Gets Diagnosed: Age and Race
Age is the single strongest risk factor. Only about 4% of U.S. breast cancer diagnoses occur in women younger than 40. The vast majority of cases are found in women over 50, with risk continuing to rise through a woman’s 60s and 70s. This is why routine mammography screening typically begins between ages 40 and 50, depending on guidelines and individual risk factors.
Incidence rates also vary by race and ethnicity. CDC data covering 1999 through 2018 shows that non-Hispanic White women had the highest overall incidence rate at about 186 per 100,000 women, followed by non-Hispanic Black women at 174 per 100,000. Hispanic women (134 per 100,000) and non-Hispanic Asian or Pacific Islander women (143 per 100,000) had lower rates. However, these numbers don’t tell the full story. Black women are more likely to be diagnosed at a younger age, more likely to have aggressive subtypes, and face significantly higher mortality rates than White women, even when diagnosed at the same stage. The gap in outcomes persists across income levels, pointing to systemic differences in care access, tumor biology, and treatment delays.
Are Cases Increasing?
Yes, particularly among younger women. CDC data shows that breast cancer incidence in women under 45 increased an average of 0.7% per year from 2001 to 2022. The trend accelerated after 2012, with rates rising 1.1% per year through 2022. Researchers are still working to explain why. Contributing factors likely include rising obesity rates, later age at first pregnancy, fewer pregnancies overall, and possibly environmental exposures, but no single cause has been pinpointed.
Among older women, incidence has been more stable or has even declined slightly in some groups. The drop in non-Hispanic White women’s rates, from 198 per 100,000 in 1999 to 186 per 100,000 in 2018, may partly reflect the sharp decline in hormone replacement therapy use after studies linked it to breast cancer risk in the early 2000s.
Survival Rates by Stage
Despite the rising number of diagnoses, breast cancer survival has improved substantially over the past several decades. The overall five-year relative survival rate in the U.S. is 92%, based on women diagnosed between 2015 and 2021. That number masks a wide range depending on how far the cancer has spread at the time of diagnosis.
- Localized (cancer confined to the breast): greater than 99% five-year survival
- Regional (cancer has spread to nearby lymph nodes): 87% five-year survival
- Distant (cancer has spread to other organs): 33% five-year survival
The vast majority of breast cancers in the U.S. are caught at the localized or regional stage, which is why the overall survival number is so high. Early detection through screening remains the most powerful tool for improving an individual’s odds. A cancer found before it leaves the breast is almost always treatable, while metastatic disease, though increasingly manageable with newer therapies, carries a dramatically different prognosis.
How Mortality Compares to Incidence
Globally, about 670,000 women die from breast cancer each year, meaning roughly 29% of those diagnosed will eventually die from the disease. In the U.S., that ratio is much lower. Approximately 42,000 to 43,000 American women die from breast cancer annually, giving the U.S. a case fatality rate well below the global average. The difference comes down to earlier detection, access to targeted treatments, and better supportive care infrastructure.
Mortality rates in the U.S. have dropped roughly 40% since their peak in the early 1990s, driven by improvements in both screening and treatment. Still, breast cancer remains the second leading cause of cancer death among American women, behind lung cancer. The persistent mortality gap between Black and White women, despite similar or lower incidence rates for Black women, remains one of the most pressing disparities in cancer care.